Published in Curr Opin Immunol on February 03, 2006
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Use of tumour-responsive T cells as cancer treatment. Lancet (2009) 1.73
Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol (2010) 1.24
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clin Cancer Res (2015) 1.15
Improvement of tissue preparation for laser capture microdissection: application for cell type-specific miRNA expression profiling in colorectal tumors. BMC Genomics (2010) 1.09
Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res (2007) 1.08
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol (2016) 1.05
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother (2010) 1.04
Regulatory T cells and innate immune regulation in tumor immunity. Springer Semin Immunopathol (2006) 0.99
Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine (2007) 0.97
A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res (2010) 0.93
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92
Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1. Cancer Immunol Res (2013) 0.91
Combination of viral oncolysis and tumor-specific immunity to control established tumors. Clin Cancer Res (2009) 0.88
The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother (2011) 0.88
Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev (2008) 0.87
Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol (2012) 0.87
Radiation and immunotherapy: Renewed allies in the war on cancer. Oncoimmunology (2012) 0.83
Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Res (2010) 0.83
Therapeutic anti-tumor vaccines: from tumor inhibition to enhancement. Clin Med Oncol (2008) 0.82
Strategies and challenges in eliciting immunity to melanoma. Immunol Rev (2008) 0.82
Does tumor size improve the accuracy of prognostic predictions in node-negative gastric cancer (pT1-4aN0M0 stage)? PLoS One (2014) 0.82
High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. Am J Pathol (2011) 0.81
New immune therapy targets tumor-associated environment: from bone marrow to tumor site. Cell Mol Immunol (2011) 0.80
B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer. Clin Cancer Res (2009) 0.79
Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site. Cell Immunol (2007) 0.78
Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J Exp Med (2016) 0.78
Two host factors regulate persistence of H7-specific T cells injected in tumor-bearing mice. PLoS One (2009) 0.76
Trends in cancer immunotherapy. Clin Med Insights Oncol (2010) 0.75
Relationships between tumor microenvironment and clinicopathological parameters in meningioma. Int J Clin Exp Pathol (2014) 0.75
Disruption of evasive immune cell microenvironment in tumors reflects immunity induced by radiation therapy. Oncoimmunology (2016) 0.75
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52
Adaptive immune cells temper initial innate responses. Nat Med (2007) 3.37
The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity (2011) 3.32
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
Recognition of host immune activation by Pseudomonas aeruginosa. Science (2005) 2.84
Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol (2004) 2.63
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
Bystander elimination of antigen loss variants in established tumors. Nat Med (2004) 2.53
Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge. Cell Host Microbe (2011) 2.46
Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol (2006) 2.44
CD95 promotes tumour growth. Nature (2010) 2.42
Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med (2002) 2.23
Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J Exp Med (2010) 2.22
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity (2002) 2.18
Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J Exp Med (2009) 2.12
Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science (2007) 2.06
Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity (2013) 2.01
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest (2006) 2.00
Lymphotoxin regulates commensal responses to enable diet-induced obesity. Nat Immunol (2012) 1.99
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med (2010) 1.97
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med (2003) 1.92
Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology (2008) 1.84
The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest (2005) 1.82
Lymphotoxin pathway directs thymic Aire expression. Nat Immunol (2003) 1.79
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest (2008) 1.71
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest (2004) 1.71
B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity. Immunity (2012) 1.70
LIGHT signals directly to intestinal epithelia to cause barrier dysfunction via cytoskeletal and endocytic mechanisms. Gastroenterology (2007) 1.70
Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med (2003) 1.68
The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A (2004) 1.63
B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation. Nat Immunol (2007) 1.61
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol (2007) 1.60
Type I interferon response and innate immune sensing of cancer. Trends Immunol (2012) 1.59
Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res (2012) 1.58
Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid. J Clin Invest (2006) 1.57
Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest (2006) 1.56
Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature (2003) 1.51
Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection. Immunity (2010) 1.50
Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med (2003) 1.49
Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol (2002) 1.45
A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science (2006) 1.44
Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol (2013) 1.44
OX40 signaling favors the induction of T(H)9 cells and airway inflammation. Nat Immunol (2012) 1.43
NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood (2005) 1.43
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med (2010) 1.40
Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity (2006) 1.40
Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res (2008) 1.39
Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am (2006) 1.37
Signaling via LTbetaR on the lamina propria stromal cells of the gut is required for IgA production. Nat Immunol (2002) 1.36
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter. Cancer Res (2014) 1.34
Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest (2008) 1.34
Hyper innate responses in neonates lead to increased morbidity and mortality after infection. Proc Natl Acad Sci U S A (2008) 1.33
Targeting stroma to treat cancers. Semin Cancer Biol (2011) 1.33
Tumor necrosis factor family members and inflammatory bowel disease. Immunol Rev (2005) 1.29
NF-kappaB2 is required for the establishment of central tolerance through an Aire-dependent pathway. J Clin Invest (2006) 1.29
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J Clin Invest (2004) 1.28
Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues. J Clin Invest (2003) 1.27
Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol Ther (2012) 1.24
TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology (2013) 1.24
Gadd45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling. J Clin Invest (2008) 1.23
The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. J Immunol (2008) 1.23
OTUD7B controls non-canonical NF-κB activation through deubiquitination of TRAF3. Nature (2013) 1.21
A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology (2012) 1.20
B and T lymphocyte attenuator tempers early infection immunity. J Immunol (2009) 1.18
The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol (2013) 1.16
Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B. J Immunol (2007) 1.16
Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun (2005) 1.15
The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. J Immunol (2005) 1.14
Specificity in cancer immunotherapy. Semin Immunol (2008) 1.11
Stimulating lymphotoxin beta receptor on the dendritic cells is critical for their homeostasis and expansion. J Immunol (2005) 1.10
Contribution of the lymphotoxin beta receptor to liver regeneration. J Immunol (2005) 1.10
Developmental pathway of CD4+CD8- medullary thymocytes during mouse ontogeny and its defect in Aire-/- mice. Proc Natl Acad Sci U S A (2007) 1.08